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ARTICLE
Prenatal dietary supplements inﬂuence the
infant airway microbiota in a randomized
factorial clinical trial
Mathis H. Hjelmsø1,5, Shiraz A. Shah 1,5, Jonathan Thorsen 1, Morten Rasmussen 1,2, Gisle Vestergaard3,
Martin S. Mortensen 3, Asker Brejnrod 3, Susanne Brix 4, Bo Chawes 1, Klaus Bønnelykke 1,
Søren J. Sørensen 3, Jakob Stokholm 1 & Hans Bisgaard 1*
Maternal dietary interventions during pregnancy with ﬁsh oil and high dose vitamin D have
been shown to reduce the incidence of asthma and wheeze in offspring, potentially through
microbial effects in pregnancy or early childhood. Here we analyze the bacterial compositions
in longitudinal samples from 695 pregnant women and their children according to inter-
vention group in a nested, factorial, double-blind, placebo-controlled, randomized trial of n-3
long-chain fatty acids and vitamin D supplementation. The dietary interventions affect the
infant airways, but not the infant fecal or maternal vaginal microbiota. Changes in overall beta
diversity are observed, which in turn associates with a change in immune mediator proﬁle. In
addition, airway microbial maturation and the relative abundance of speciﬁc bacterial genera
are altered. Furthermore, mediation analysis reveals the changed airway microbiota to be a
minor and non-signiﬁcant mediator of the protective effect of the dietary interventions on risk
of asthma. Our results demonstrate the potential of prenatal dietary supplements as
manipulators of the early airway bacterial colonization.
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Asthma and other chronic inﬂammatory diseases are agrowing burden in the developed world causing sub-stantial morbidity and mortality1. There is substantial
evidence pointing to the early life as a critical window for disease
development, beginning already in the intrauterine environment2.
This concept was proven in recent clinical trials of dietary
interventions with n-3 long-chain polyunsaturated fatty acids
(LCPUFA) and high dose vitamin D in pregnancy, resulting in
signiﬁcantly reduced risk of asthma and wheeze in childhood3–6.
The mechanisms for these effects are unknown. However, both
have been shown to affect the developing immune system; n-3
LCPUFA compete with arachidonic acid-derived eicosanoids,
modulate key regulatory cytokines, and is involved in the
maturation of Th cells7,8, whereas vitamin D, and associated
vitamin D receptors (VDRs), are involved in the maturation of
regulatory T-cells (Tregs), the production of antimicrobial pep-
tides, and the production of the tight junction proteins cadher-
ins9–11. In addition to being immune regulatory, n-3 LCPUFA
and vitamin D intake have been associated with gut microbial
changes in both human observational studies and murine inter-
vention models12–14.
In recent years the human microbiome has received increased
attention as a potential contributor to disease development,
especially the earliest microbial compositions15. In relation to
asthma and allergic diseases, both early life bacterial composition
in the gut16–18 and speciﬁc bacterial genera in the neonatal
airways19,20 have been associated with increased disease risk later
in life.
The aim of this study is to analyze if maternal supple-
mentation with n-3 LCPUFA and vitamin D affects the
microbiota of mother and child. Furthermore, we want to
elucidate if the protective effect of these supplementations on
asthma can be mediated by the microbiota. This is done using
the Copenhagen Prospective Studies on Asthma in Childhood
2010 (COPSAC2010) mother-child cohort, consisting of 736
women and their children participating in a nested factorial
randomized clinical trial of n-3 LCPUFA and vitamin D sup-
plementation in pregnancy21. Microbiota samples were
acquired from the pregnant women (vagina) and at regular
intervals during infancy of the child (airways (hypopharyngeal
aspirates), and feces) and are in this study analyzed with 16S
rRNA gene amplicon sequencing.
In our study the dietary interventions affects the infant airways,
but not the infant fecal or maternal vaginal microbiota. We
observe changes in overall beta diversity, which in turn associates
with a change in immune mediator proﬁle. The interventions also
affects the airway microbial maturation and the relative abun-
dance of speciﬁc bacterial genera. Finally, using mediation ana-
lysis we observe that the changed airway microbiota is a minor
and non-signiﬁcant mediator of the protective effect of the dietary
interventions on risk of asthma.
Results
Study population. Of the 736 women participating in the
COPSAC2010 cohort, 693 were included in the n-3 LCPUFA
trial and 580 in the vitamin D trial and delivered at least
one microbial sample to our study. 695 children born to these
women were included in the n-3 LCPUFA trial and 581 in
the vitamin D trial and delivered at least one microbial sample.
The same cohort was subject to both interventions in a factorial
design with some mothers receiving only placebo, some
mothers receiving either supplement, and some mothers
receiving both. Randomized allocation among the included
women produced comparable groups with respect to baseline
characteristics (Table 1).
Longitudinal development of the microbial community. We
successfully sampled and sequenced the V4 region of the 16S
bacterial rRNA gene in 4991 samples, with a mean sequencing
depth of 54,682. The total number of unique OTUs found across
all samples was 6846 (see Supplementary Table 1). Here follows a
short resume of the microbial longitudinal development in the
maternal vaginal, and infant fecal and airway samples of the
COPASAC2010 mother-child cohort: In the maternal vaginal
samples the average bacterial composition in samples from week
24 and 36 appeared similar and were dominated by the genera
Lactobacillus and Gardnerella accounting for ~80% and 10% of
the sequencing reads, respectively (Fig. 1).
In the infant fecal samples the composition in samples from
the infants taken at 1-week and 1-month were dominated by
Biﬁdobacterium, Enterobacteriaceae, and Bacteroides. In the 1-
year fecal samples, we observed a signiﬁcant decrease in
Enterobacteriaceae, Staphylococcus, Streptococcus and Biﬁdobac-
terium in favor of Bacteroides and a generally larger proportion of
overall lower-abundance genera, including Faecalibacterium and
Prevotella.
In the infant airway samples the three major genera taken at 1-
week after birth were Staphylococcus, Streptococcus and Morax-
ella. In the subsequent samples from 1-month and 3-months, we
observed a gradual increase in the relative abundance of
Streptococcus, Moraxella, and Haemophilus, as well as a decrease
in Staphylococcus. More details on the individual sample types
can be found in previous publications16,22 (Mortensen, M. S. et al.
Stability of Vaginal microbiota during pregnancy and its
importance for early infant microbiota. Unpublished)
Effects of the n-3 LCPUFA and vitamin D interventions. The
vaginal samples were taken at pregnancy week 36, twelve weeks
into the supplementation with n-3 LCPUFA and vitamin D,
totaling 665 samples, and did not show any signiﬁcant differences
in alpha diversity as a result of either intervention calculated
using the Shannon index (see Supplementary Fig. 1). Similarly, no
signiﬁcant changes in beta diversity were observed in the vaginal
samples as a result of the two dietary interventions (Table 2).
The infant fecal microbiota was sampled at 1-week, 1-month,
and 1-year after birth, totaling 552, 607, and 625 samples,
respectively. No signiﬁcant effects were seen of the two dietary
interventions neither on alpha diversity (Supplementary Fig. 1)
nor beta diversity (Table 2) at any of the time points.
Infant airway samples were taken at 1-week, 1-month, and 3-
months, totaling 544, 645, and 622 samples, respectively. No
effects were seen on alpha diversity at any of the three time points
(see Supplementary Fig. 1). However, at 1-month of age, both
interventions affected the microbial composition (PERMA-
NOVA, n-3 LCPUFA (F= 3.74, p= 0.005), and Vitamin D
(F= 4.228, p= 0.004) (Table 2). No interaction between the two
interventions was observed (PERMANOVA, F= 0.49, p= 0.785),
and the effect of each intervention remained signiﬁcant after
adjusting for common covariates, which might affect the
microbiota (delivery, older siblings, antibiotics during pregnancy,
antibiotics in the ﬁrst month of life, birth season, cat at home at
birth, dog at home at birth, and sex). To study the microbial
composition effects at 1-month in more detail a differential
abundance (DA) analysis was made on the most abundant phyla
and genera (Fig. 2). Both interventions led to a signiﬁcant
decrease in Firmicutes and a corresponding increase in
Proteobacteria (Fig. 2a, b). These changes seemed mainly to be
driven by decreases in the genera Streptococcus and Staphylo-
coccus with an increase in Moraxella, although neither of these
individual changes were statistically signiﬁcant (Fig. 2c, d). In
addition, n-3 LCPUFA supplementation resulted in a signiﬁcant
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Table 1 Baseline characteristics of the n-3 LCPUFA and Vitamin D randomized controlled trials.
Category Variable Overall (n (%)) n-3 LCPUFA
(n (%))
Placebo (n (%)) Vitamin D
(n (%))
Placebo (n (%))
n 693 344 349 294 286
Socioeconomics
(maternal)
Age; mean (sd) 32.29 (4.36) 32.33 (4.27) 32.24 (4.46) 32.50 (4.33) 32.01 (4.32)
Level of education:
Low 55 (7.9) 25 (7.3) 30 (8.6) 20 (6.8) 25 (8.7)
Medium 446 (64.4) 221 (64.2) 225 (64.5) 185 (62.9) 189 (66.1)
High 192 (27.7) 98 (28.5) 94 (26.9) 89 (30.3) 72 (25.2)
Income level:
Low 67 (9.7) 33 (9.6) 34 (9.7) 27 (9.2) 27 (9.4)
Medium 366 (52.9) 178 (51.9) 188 (53.9) 151 (51.4) 153 (53.5)
High 259 (37.4) 132 (38.5) 127 (36.4) 116 (39.5) 106 (37.1)
During pregnancy Smoking 54 (7.8) 21 (6.1) 33 (9.5) 20 (6.8) 26 (9.1)
Cat or dog in home 234 (34.1) 117 (34.4) 117 (33.8) 88 (30.3) 105 (37.0)
Antibiotic use 253 (36.6) 128 (37.3) 125 (35.8) 102 (34.8) 103 (36.0)
Child Sex (male) 354 (51.1) 168 (48.8) 186 (53.3) 154 (52.4) 144 (50.3)
Race (caucasian) 664 (95.8) 332 (96.5) 332 (95.1) 282 (95.9) 274 (95.8)
Season of birth:
Winter 212 (30.6) 98 (28.5) 114 (32.7) 107 (36.4) 102 (35.7)
Spring 185 (26.7) 94 (27.3) 91 (26.1) 53 (18.0) 53 (18.5)
Summer 148 (21.4) 74 (21.5) 74 (21.2) 62 (21.1) 57 (19.9)
Fall 148 (21.4) 78 (22.7) 70 (20.1) 72 (24.5) 74 (25.9)
Duration of
breastfeeding
245 (155) 249 (159) 240 (156) 243 (145) 247 (165)
Birth Preterm delivery 27 (3.9) 12 (3.5) 15 (4.3) 10 (3.4) 9 (3.1)
Nulliparity 318 (45.9) 153 (44.5) 165 (47.3) 121 (41.2) 140 (49.0)
Antibiotics to mother 221 (32.0) 111 (32.4) 110 (31.7) 97 (33.2) 87 (30.5)
Antibiotics to child 18 (2.6) 10 (2.9) 8 (2.3) 5 (1.7) 9 (3.2)
Hospitalized 77 (11.1) 39 (11.3) 38 (10.9) 27 (9.2) 27 (9.5)
Delivery mode:
Acute CS 84 (12.1) 47 (13.7) 37 (10.6) 39 (13.3) 33 (11.5)
Vaginal 544 (78.5) 266 (77.3) 278 (79.7) 225 (76.5) 226 (79.0)
Planned CS 65 (9.4) 31 (9.0) 34 (9.7) 30 (10.2) 27 (9.4)
Percentages or standard deviations in parenthesis. No signiﬁcant allocation differences were observed (chi-sq or t-test, p < 0.05)
Vagina (mother) Feces (child) Airway (child)
1 week 1 month 1 year
(n = 731) (n = 665) (n = 552) (n = 607) (n = 625) (n = 544) (n = 645) (n = 622)
Preg.week 24 Preg.week 36 1 week 1 month 3 months
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Fig. 1 Bacterial community composition in children’s feces and airway, and maternal vaginal samples over time. The community composition is
represented by the 12 most abundant genera. Each bar is represented by 544 to 665 samples. Source data are provided as a Source Data ﬁle.
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decrease in the two genera Gemella and Veillonella (Fig. 2c). An
additional DA analysis was performed on OTU level including
also less abundant OTUs, hoping to ﬁnd rare but important taxa
affected by the interventions (Supplementary Fig. 2). n-3
LCPUFA signiﬁcantly (metagenomeSeq, p < 0.05) increased the
abundance of four OTUs, and decreased the abundance of six
OTUs including three Veillonella (Supplementary Fig. 2, and
Supplementary Table 2). Vitamin D increased the abundance of
six OTUs including two Neisseria and two Haemophilus while
decreasing the relative abundance of seven Streptococcus OTUs,
ﬁve of which was putatively identiﬁed a S. pneumoniae, and the
rest as S. mitis or S. oralis. However, none of the effects on single
OTUs were signiﬁcant after correcting for multiple testing (FDR,
p < 0.1).
The 1-week and 3-month infant airway samples did not reveal
any beta diversity differences between the intervention groups
(Table 2).
Additive effects of n-3 LCPUFA and Vitamin D. Since both
interventions showed signiﬁcant effects on the 1-month airway
microbial composition and similar shifts on both phylum and
genus levels, the possibility of an additive effect was further
explored using a PCoA stratiﬁed by the two intervention groups
Table 2 The effects of n-3 LCPUFA and Vitamin D vs. placebo on microbial beta-diversity.
Compartment Time point n-3 LCPUFA F/R2/P-value Vitamin D F/R2/P-value
Maternal vagina Week 36 1.517/0.002/0.205 0.824/0.002/0.399
Child feces 1-week 0.172/0.001/0.969 0.350/0.002/0.955
1-month 0.827/0.001/0.472 0.339/0.001/0.865
1-year 1.270/0.002/0.250 0.277/0.001/0.973
Child airway 1-week 0.277/0.001/0.987 0.350/0.001/0.955
1-month 4.228/0.007/0.004 3.740/0.007/0.005
3-month 0.172/0.000/0.993 1.140/0.002/0.297
Effects were quantiﬁed with F statistics, R2, and P-values, as determined by PERMANOVA on weighted UniFrac distances. Signiﬁcant p-values (p < 0.05) are shown in bold
Other phylum
Actinobacteria
Proteobacteria
Firmicutes
a
Other genus
Neisseria
Veillonella
Family enterobacteriaceae
Gemella
Corynebacterium
Haemophilus
Moraxella
Staphylococcus
Streptococcus
c
0.00 0.25 0.50 0.75 1.00 0.00 0.25 0.50 0.75 1.00
0.00 0.25 0.50 0.75 1.00 0.00 0.25 0.50 0.75 1.00
b
Average relative abundance Average relative abundance
d
Placebo n-3 LCPUFA Vitamin D
0.001
0.003
ns
ns
0.014
0.041
ns
ns
ns
ns
ns
ns
ns
0.005
ns
0.002
ns
NA
ns
ns
ns
ns
ns
ns
ns
ns
ns
NA
Fig. 2 Relative bacterial abundances stratiﬁed by intervention groups for the 1-month airway samples. Relative abundances are shown at the phylum-
level (a and b), and genus-level (c and d). The three most abundant phyla and nine most abundant genera are shown. Phylum level DA statistics were
performed using Wilcoxon rank sum test and genus level DA using the metagenomeseq feature model. Boxplots with ﬁrst and third quartiles
corresponding to the lower and upper hinge, the median represented by a vertical line, the mean by a black dot, upper/lower whiskers extend to the
largest/smallest value no further than 1.5 * inter-quartile range (IQR) from the hinge, and outliers are shown as gray circles. In bold are crude p-values
reaching FDR corrected signiﬁcance at level 0.1. n= 653 and 541 independent samples for the n-3 LCPUFA (a+ c) and Vitamin D (b+ d) plot, respectively.
Source data are provided as a Source Data ﬁle.
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(Fig. 3). We observed a rightward shift on PCo1 according to
intervention, i.e., with the group receiving both n-3 LCPUFA and
vitamin D on the right, the groups receiving only one interven-
tion in the center, and the group receiving placebo in both
interventions on the left (p < 0.001, Wilcoxon rank sum test).
Building on this concordance between n-3 LCPUFA and vitamin
D effects, a correlation analysis was performed, using the number
of interventions against the relative abundances of individual
phyla and genera (Fig. 4). This conﬁrmed the previous results of
the individual interventions, showing a stepwise signiﬁcant
decrease in Firmicutes and an increase in Proteobacteria as a
function of the number of interventions received (Fig. 4a). At the
genus level, Streptococcus signiﬁcantly decreased and Moraxella
increased (Fig. 4b), although these exploratory ﬁndings did not
reach FDR corrected signiﬁcance at level 0.1.
Additive increases were also seen for Neisseria, Corynebacter-
ium, and Haemophilus and additive decreases for Staphylococcus,
Gemella and Veillonella, although neither of these trends were
statistically signiﬁcant (Spearman’s rank correlation coefﬁcient,
p > 0.05) (Fig. 4b). The grouping of the cohort into number of
interventions (0, 1, and 2) still produced comparable groups with
respect to baseline characteristics (Supplementary Table 3).
Mediation analysis. After documenting the effect of n-3
LCPUFA and Vitamin D on the 1-month airway microbiota,
we wanted to study if these changes could serve as a mediator for
the previously observed protective effect of the interventions on
childhood asthma. To do this we used PCo1 from Fig. 3 as a
surrogate of the intervention induced microbiota changes in a
mediation analysis using parametric survival regression models
with the debut of persistent wheeze or asthma as end-points
(Supplementary Table 4). We found that the 1-month airway
microbiota effect from n-3 LCPUFA supplementation could
account for an estimated 9% of the total asthma prevention effect
till age 5 years (p= 0.11) previously published3. Similarly, 5.5% of
the previously published vitamin D effect on persistent wheeze till
3 years of age could be mediated by changes in the 1-month
airway microbiota (p= 0.39)4. However, none of the minor
mediation effects were statistically signiﬁcant, suggesting that the
microbial changes observed as a result of the two dietary sup-
plements had a minor or no effect on later risk of asthma.
The interventions and gut and airway microbial maturation.
As early microbial colonization patterns have previously been
linked to later health outcomes we wanted to study the inﬂuence
of the interventions on the early life microbial maturation. To do
that we calculated the microbiota-by-age z-score (MAZ) for the
gut and airway samples, with both compartments represented by
three sampling time points23. No effect of either intervention on
MAZ was seen on any of the gut samples, and on the 3-month
airway samples. However, n-3 LCPUFA decreased the airway
maturation in the 1-week time point (t-test, p= 0.004), and
increased the maturation in the 1-month time point (t-test, p=
0.01). The Vitamin D intervention had a weaker and not sig-
niﬁcant effect, although the same trend was observed at both
timepoints. An additive effect of the interventions was also
observed decreasing the MAZ with 0.2 per intervention (p=
0.007) at the 1-week and increasing with 0.1 per intervention
(p= 0.05) at 1-month.
Interventions, airway microbiota, and airway immunology. To
study the mechanism of the observed changes in airway micro-
biota in the 1-month time point, we analyzed the association
between PCo1 from Fig. 3, affected by both interventions, and
airway immunology taken at the same time point. We found a
signiﬁcant positive association between PCo1 and CCL4, TNF-α,
CXCL8, and IL-1β, and a signiﬁcant negative association between
PCo1 and CCL2, and CCL17 (Fig. 5).
Effect modulation by mode of delivery. To investigate possible
mechanisms of the intervention effects on the 1-month airway
microbiota, we examined potential effect modulation by mode of
delivery. If the interventions had direct effects on the maternal
gut microbiota, an assumed transfer to the child could be inter-
rupted by cesarean section delivery. However, no signiﬁcant
interaction was observed neither for delivery mode on the global
beta diversity variation (adonis, p= 0.58) nor the shift in PCo1
(linear model, p= 0.29) of the 1-month airway samples.
Discussion
Third trimester supplementation with n-3 LCPUFA and high
dose vitamin D had signiﬁcant effects on the infant 1-month
airway microbiota, with the interventions affecting the overall
population structure and relative abundances of individual genera
in a similar and additive manner. This suggests that both
micronutrients share a common pathway modifying the infant
airway microbiota. Alternatively, both lack of n-3 LCPUFA and
vitamin D could be limiting factors of a general optimal fetal
immune development, which would explain the observed parallel
bacterial effects. Yet, such additive effects were not seen in our
clinical end-points.
The effects of the interventions affected the relative abundance
of several bacterial genera previously associated with inﬂamma-
tion, asthma and wheeze. The n-3 LCPUFA intervention resulted
in a signiﬁcant reduction in Gemella and Veillonella (Fig. 2), both
positively associated with the development of asthma in a pre-
vious study of the same cohort24. Furthermore, in our study, a
reduction in the genus Streptococcus was found to be signiﬁcant
–0.005
–0.004
0.000
0.004
0.000 0.005
Placebo/placeboPlacebo/vitamin Dn-3 LCPUFA/Placebon-3 LCPUFA/vitamin D
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o2
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%)
Fig. 3 Ordination of 1-month airway samples stratiﬁed by intervention
group. An additive effect is apparent in the right shift observed over PCo1
as samples are subject to either (n-3 LCPUFA/placebo (n= 125), or
placebo/vitamin D (n= 141)) or both prenatal dietary interventions (n-3
LCPUFA/vitamin D (n= 131)) compared to double-placebo (placebo/
placebo (n= 144)) (p < 0.001, Wilcoxon rank sum test). Boxplots represent
the PCo1 values of each intervention group with ﬁrst and third quartiles
corresponding to the lower and upper hinge, the median represented by a
vertical line, and the upper/lower whiskers extend to the largest/smallest
value no further than 1.5 * inter-quartile range (IQR) from the hinge. Source
data are provided as a Source Data ﬁle.
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in the additive model of the two interventions, and the abundance
of seven Streptococcus OTUs both belonging to pathogenic and
commensal species were signiﬁcantly reduced as an effect of
Vitamin D (Supplementary Fig. 2, and Supplementary Table 2).
This genus has previously been associated with later asthma
development when detected in the airways during early
infancy19,25. Streptococcus-rich, Gemella-rich, and Veillonella-rich
bacterial compositions have been shown to associate with an
Other phylum
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a
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Family enterobacteriaceae
Gemella
Corynebacterium
Haemophilus
Moraxella
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Average relative abundance
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b
0.0001
0.0004
ns
ns
0.0343
ns
0.0143
ns
ns
ns
ns
ns
ns
NA
Fig. 4 Additive effects of the interventions on the 1-month airway samples. Relative abundances are shown on (a) Phylum level and (b) Genus level. The
correlation was analyzed by Spearman’s rank correlation coefﬁcient and p-values below 0.05 are shown. The p-values in b are not signiﬁcant when
correcting for multiple testing using an FDR corrected signiﬁcance of 0.1. Boxplots with ﬁrst and third quartiles corresponding to the lower and upper hinge,
the median represented by a vertical line, the mean by a black dot, upper/lower whiskers extend to the largest/smallest value no further than 1.5 * inter-
quartile range (IQR) from the hinge, and outliers are shown as gray circles. n= 144, 266, and 131 for the zero, one, and two intervention groups,
respectively. Source data are provided as a Source Data ﬁle.
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Fig. 5 Associations between intervention driven microbiota changes in the 1-month airway and neonatal airway immunology. PCo1 from Fig. 3 was used
as a metric for the intervention driven microbial changes and analyzed with the airway concentration of 20 local immune mediators in the nose, also
measured at the 1-month time point. Linear models show that PCo1 is associated with several immune mediators, expressed as relative concentration ratios
of immune mediators per standard deviation (SD) increase in PCo1, n= 585 independent samples. Error bars represent 95% conﬁdence intervals. Source
data are provided as a Source Data ﬁle.
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inﬂammatory phenotype in healthy adults, with increasing levels
of Th17 cytokines including IL-1a and IL-1B26. In addition,
Veillonella has been shown to correlate positively with a number
of inﬂammatory cells and exhaled nitric oxide (eNO), further
suggesting a causal relationship between a distinct airway
microbiota, systemic and topical inﬂammation, and asthma
pathogenesis27.
While we found signiﬁcant effects on the 1-month airway
microbiota, there were no effects on the 1-week and 3-month
time points. The very dynamic initial colonization and develop-
ment of the airway microbiota, as described previously, may in
part explain this22,28. This was also apparent in the effect of the
interventions on airway maturation, possibly inﬂuencing coloni-
zation progression in the dynamic period of our two earliest time
points, but no longer detectable at the 3-month time point, shown
in the litterature to be a more stable period in airway microbial
development29. However, the airway MAZ index did not
associate with later asthma risk, suggesting that the maturation
effects might be a side effect of the interventions clinical effects
instead of the cause. The speculated immune-priming effects of
the interventions and the observed clinical effects on later asthma
suggests that the observed mechanism could penetrate in a certain
so-called “window of opportunity” in early infancy; a period
where the developing immature immune system and the highly
dynamic airway microbiota mutually inﬂuence each other30. This
time-sensitivity has been observed in several other microbiome
studies, although the precise demarcations of such windows are
not yet clearly deﬁned16,18,23. Interestingly, there were no
detectable effects on the maternal vaginal microbiota in preg-
nancy, nor the early gut microbiota of the children, which for
Vitamin D has been observed before in a similar high dose
vitamin D cohort study31.
The mechanism whereby the interventions affected the airway
bacteria of the neonates of our study is still unknown, although
we observed strong associations between the airway microbiota
composition most affected by the interventions and several
immune mediators including proinﬂammatory TNF-α and IL-1β.
This could suggest that a more active and stimulated young
immune proﬁle affected the colonization pattern of the early
airways, which has been linked to a reduced risk of inﬂammatory
diseases in later life32,33. However, the direction of causality could
also be opposite, with speciﬁc bacteria leading to a properly sti-
mulated immune maturation. Several other possible mechanisms
can be found in the litterature, e.g., with n-3 LCPUFAs being
known for their anti-inﬂammatory effects, and the modulation of
eicosanoid mediator synthesis is the likely primary mode of
action related to asthma pathogenesis8,34. n-3 LCPUFAs have also
been linked to a range of other anti-inﬂammatory mechanisms
including the production of resolvins and protectins, and the
reduction of pro-inﬂammatory mediators and oxidative
stress35,36. It is unclear whether the maternal supplement only
worked through a fetal priming effect37,38, or if higher levels were
still present after birth, directly affecting the child immune cells.
We have previously demonstrated that the vitamin D supple-
mentation upregulated local immune mediators in the airways
related to type 1, type 2, type 17, and regulatory immune paths, at
the age of 1-month, which could inﬂuence the bacterial coloni-
zation dynamics4, but the changes in the airway microbiota, as
demonstrated in this study, could also be interacting with the
immune maturation as discussed previously. Another possible
pathway is an increased production of the antimicrobial peptides
cathelicidin and β-defensin by the bronchial epithelial cells, which
is stimulated by the hormonally active form of vitamin D39.
Despite affecting airway bacteria previously associated with
inﬂammatory diseases, our results suggest that only a minor part
of the protective effect on asthma/persistent wheeze from the
prenatal n-3 LCPUFA (9%) and high-dose vitamin D (5%) sup-
plementations could be explained by the observed early life
microbial alterations in the airways, and this effect is uncertain as
none of the mediation effects reached statistical signiﬁcance.
However, we believe that this is mainly a power issue as the
overall clinical effects of n-3 LCPUFA just reaches signiﬁcance.
Splitting this effect into mediated (via microbiota) and direct (not
mediated by microbiota), renders signiﬁcance hard to achieve, as
the clinical effects of n-3 LCPUFA is probably working through
many different mechanistic pathways. These could include
changes in fetal development including lung organogenesis,
immune maturation and modulation of DNA methylation
states38.
The major advantage of this study is that the effects of n-3
LCPUFA and vitamin D on the maternal and infant microbiota
were tested in a double blind randomized clinical trial, reducing
the risk of possible confounding inherent to observational studies.
Another strength of this study is the clinical surveillance of the
COPSAC2010 cohort, including longitudinal sampling from 695
mother-child pairs. All study participants were investigated by in-
house trained research pediatricians and medical personnel
ensuring comparable measurements in regard to both microbiota
sampling and clinical diagnosis of asthma and persistent wheeze.
It is another strength that several biological compartments were
sampled in this study, including maternal vaginal and infant gut
and airways. It is a limitation that additional compartments,
including the maternal gut before and after intervention and
infant microbiota right after birth, were not sampled. This would
have allowed us to detect a possible fecal bacterial transfer event
during birth40–43. However, an intervention manipulated mater-
nal bacterial transfer during delivery was not observed in this
study as the intervention effects were not modiﬁed by cesarean
section. In addition, closer airway sampling around the 1-month
time point could have helped in pinpointing the exact period of
the effect of the two interventions. This study was performed
using 16S rRNA gene amplicon sequencing, characterizing the
effects of the interventions on the bacterial community compo-
sition, which does not cover possible effects on fungi, parasites
and viruses inhabiting the human body. In addition, the techni-
que is insensitive to functional differences between communities,
which could be explored further in future studies employing
metagenomic sequencing44.
Methods
Experimental design. The study was embedded in the population-based COP-
SAC2010 prospective mother-child cohort of 736 women and their children fol-
lowed from week 24 of pregnancy, with the primary clinical endpoint persistent
wheeze or asthma, which was diagnosed according to a previously validated
quantitative algorithm3,4,21.
Microbial sampling. Maternal vaginal swabs were sampled at the research unit at
week 24 and 36 of pregnancy45. The infant airway was sampled using hypophar-
yngeal aspirates obtained at ages 1-week, 1-month, and 3-months, using a soft
suction catheter passed through the nose19. Infant fecal samples were collected 1-
week, 1-month, and 1-year after birth, either at the research clinic or by the parents
at home using detailed instructions. Each fecal sample was mixed on arrival with
10% vol/vol glycerol broth. All samples were stored at −80 °C until DNA
extraction.
Immunological sampling. Airway immunology was assessed 1-month after birth
by measuring unstimulated levels of 20 cytokines and chemokines in airway
mucosal lining ﬂuid sampled by nasosorption4,46–48. Brieﬂy, a synthetic absorptive
matrix (ﬁbrous hydroxylatedpolyester sheets, Accuwik Ultra (cat no. SPR0730),
Pall Life Sciences, Portsmouth, Hampshire, UK) was inserted in both nostrils for
2 min and stored at −80 °C until protein extraction, which was done by immersing
both ﬁlter strips in 300 μL Milliplex assay buffer (Millipore, Cat no. L-AB, Mass)
containing 1 protease inhibitor tablet (Roche) per 25 mL buffer, and then trans-
ferred to the cup of a cellulose acetate tube ﬁlter (0.22 μm) placed in an Eppendorf
tube (Spin X centrifuge tube ﬁlter, cat no. CLS8161, Sigma-Aldrich, St Louis, Mo).
The tube was centrifuged for 5 min at 16,000×g, 4 °C. The obtained protein extract
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14308-x ARTICLE
NATURE COMMUNICATIONS |          (2020) 11:426 | https://doi.org/10.1038/s41467-020-14308-x | www.nature.com/naturecommunications 7
was stored immediately at −80 °C until determination of immune mediators
(cytokines and chemokines) using high-sensitivity electrochemiluminescence
multiplex assays (Meso Scale Discovery, Rockville, Maryland). The 20 cytokines
and chemokines include interleukin (IL)-12p70, CXCL10 (interferon gamma-
induced protein [IP]-10), interferon (IFN)-γ, tumor necrosis factor (TNF)-α, CCL4
(macrophage inﬂammatory protein [MIP]-1β), CCL2 (monocyte chemoattractant
protein [MCP]-1), CCL13 (MCP-4), IL-4, IL-5, IL-13, CCL11 (eotaxin-1), CCL26
(eotaxin-3), CCL17 (thymus-regulated and activation-regulated chemokine
[TARC]), CCL22 (macrophage-derived chemokine [MDC]), IL-17, IL-1β, CXCL8
(IL-8), transforming growth factor (TGF)-β1, IL-10, and IL-2.
Ethics. The study was conducted in accordance with the guiding principles of the
Declaration of Helsinki and was approved by the National Committee on Health
Research Ethics (H-B-2008-093 and H-B-2009-014), the Danish Data Protection
Agency (2015-41-3696), and Danish Health and Medicines Authority (2612-3959).
Both parents gave oral and written informed consent before enrollment. The trials
are registered with ClinicalTrials.gov, identiﬁer: NCT00798226 and NCT00856947.
Dietary supplements. The women were randomized 1:1 to a daily dose of 2.4 g of
n−3 LCPUFA (55% EPA and 37% DHA) in triacylglycerol form (Incromega TG33/
22, Croda Health Care) or placebo (olive oil, containing 72% n–9 oleic acid and 12%
n−6 linoleic acid (Pharma-Tech A/S)), given from pregnancy week 24 to 1 week
postpartum3. In addition, the women were randomized 1:1 to a daily dose of 2400
IU vitamin D3 supplementation or matching placebo tablets (Camette A/S) from
pregnancy week 24 to 1 week postpartum4. All women were instructed to continue
supplementation of 400 IU of vitamin D3 during pregnancy as recommended by the
Danish National Board of Health; thus, the study is a dose comparison of 2800 IU/d
vs. 400 IU/d of vitamin D3 supplementation. These two interventions were crossed
in a factorial design, yielding four groups (n-3 LCPUFA/vitamin D, n-3 LCPUFA/
placebo, placebo/vitamin D and placebo/placebo).
DNA extraction, sequencing, and bioinformatics. The DNA was extracted using
the Mobio PowerMAG soil DNA isolation kit on the epMotion 5075 robotic
platform acccording to manufacturer’s protocol. Extracted DNA was ampliﬁed
using a two-step PCR reaction with the 16S rRNA gene primers 515 F (5′-
GTGCCAGCMGCCGCGGTAA-3′) and 806 R (5′-GGACTACHVGGGTWTC-
TAAT-3′) targeting the V4 region27. The PCR conditions for the ﬁrst PCR-step
were 2 min of denaturation at 94 °C, followed by 30 cycles of 20 s at 94 °C
(denaturing), 30 s at 56 °C (annealing), and 40 s at 68 °C (elongation), with a ﬁnal
extension at 68 °C for 5 min. In the second PCR-step the sequencing primers and
adapters were added using the PCR conditions as above but with only 15 cycles.
Finished libraries were quantiﬁed, equimolary pooled and concentrated using using
the DNA Clean & Concentrator−5 Kit (Zymo Research, Irvine, CA, USA)
according to the manufacturer’s instructions. Sequencing was done on the Miseq
platform using the v2 kit (paired-end 250 bp reads). Sequencing reads were de-
multiplexed by the Miseq Controller Software, trimmed using biopieces49, checked
for chimeras using usearch50,51 OTU clustered using UPARSE52, and classiﬁed
using Mothur53,16.
Statistical analysis. All data analyses were conducted using the statistical software
R v3.3.054. Samples with less than 2000 reads (n= 146, 7.5%) were omitted from
the analysis. Sequencing and taxonomy data handling, taxonomical agglomeration,
alpha diversity (analyzed using the Shannon Index) and beta diversity (analyzed
using weighted UniFrac distances55) estimates were done using the R-package
“phyloseq”56. Differences in beta diversity were tested using permutational mul-
tivariate analysis of variance (PERMANOVA)57 with 10,000 permutations and
visualized with principal coordinates analysis (PCoA) plots. Differential abundance
was tested with the Wilcoxon rank sum test on phylum level and with the spe-
cialized tool for DA analysis of sparse data, the metagenomeSeq feature-model58,
on genus and OTU level using dietary supplement as predictor, after ﬁltering away
sparse and rare genera (≥10% presence, ≥0.01% mean relative abundance). Detailed
taxonomic assignment of signiﬁcant OTUs was attempted using Blastn59 against
the default NCBI nr/nt database, and all named bacterial hits with highest %
identity and % query coverage was reported. Multiple inferences were controlled
using the False Discovery Rate Control by Benjamini-Hochberg and signiﬁcance
thresholds were reported at level 0.1 owing to the exploratory nature of the study.
Additive effects of the two dietary supplements were analyzed using the Spearman
correlation coefﬁcient. The two factor factorial design was subsequently repre-
sented as a single factor with three levels (0: placebo/placebo, 1: placebo/vitamin D
or n-3 LCPUFA/placebo and 2: n-3 LCPUFA/vitamin D) and compared with
microbiota markers (phyla, genera and PCoA features) using Spearman’s corre-
lation coefﬁcient. Microbiota-by-age z-scores (MAZ) of the airway and gut were
calculated using a random forest model16,23,29, using a 10-fold cross validation
procedure with calculation of: microbial maturity (MM)= (predicted microbiota
age−median microbiota age); and MAZ= (MM/SD) of predicted microbiota age
as metrics. In order to estimate the extent of asthma reduction from the individual
interventions that could be mediated via 1-month airway microbiota modulations,
parametric survival regression models, modeling time to asthma onset were built
using the intervention and the ﬁrst PCoA component from weighted UniFrac
distances as covariates. This was done using the R-package “Survival”60 and
“mediation”61. As such, the (average) direct effect (ADE) reﬂects the part of the
intervention effect on asthma which cannot be explained by microbiota alterations,
whereas the (average) causal mediated effect (ACME), represents the part of the
intervention effect on asthma caused by microbiota changes. The proportion of the
ACME effect in relation to the total intervention effect, in a simple metric, reﬂects
the proportion of the intervention clinical effect on asthma mediated through the
airway microbiota. Immune mediator concentrations (1-month time point) were
standardized, total-sum normalized per sample, log-transformed and z-scored
before further analysis. Immune mediators were analyzed in relation to PCo1 from
Fig. 3 using linear models.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Summary and feature-level data underlying Figs. 1–5, and Supp Figs. 1, 2 are provided as
Source Data ﬁles. The 16S rRNA gene sequences are publicly available at Sequence Read
Archive (SRA) [https://www.ncbi.nlm.nih.gov/sra/] with the accession numbers
PRJNA340273, PRJNA417357, PRJNA576765, and PRJNA579012. All other data that
supports the ﬁndings in this study, including clinical data, are available from the
corresponding author upon reasonable request. Participant-level personally identiﬁable
data are protected under the Danish Data Protection Act and European Regulation 2016/
679 of the European Parliament and of the Council (GDPR) that prohibit distribution
even in pseudo-anonymized form, but can be made available under a data transfer
agreement as a collaboration effort.
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